reason report
strong commerci guidanc rais pipelin keep us
sidelin
bottom line report earn provid increment
updat compani clinic develop program jakafi
continu deliv strong revenu growth modestli beat
estim consensu revenu stream
larg in-lin pipelin updat mostli expect
anticip near-term focu top-line data phase
trial evalu next-gen jak inhibitor itacitinib
steroid-nav acut gvhd readout expect believ
expect program posit rel high given
jakafi result similar steroid refractori acut gvhd set
though note steroid-na set gvhd higher bar
jakafi revenu beat today partial driven better-
than-expect growth gvhd increas expect itacitinib
program advanc jak frontlin set view solid
commerci execut jakafi backbon instrument long
thesi continu believ rel lacklust pipelin
date heighten import near-term binari catalyst like
trial bolster long invest thesi clear
winner emerg pipelin remain mp
jakafi commerci execut strong beat estim
jakafi revenu repres yoy growth beat
estim consensu jakafi revenu growth
appear strong driven increas patient demand across
indic jakafi penetr
myelofibrosi opportun polycythemia vera
pv opportun jakafi sale recent approv steroid-
refractori gvhd set explicitli quantifi manag
suggest sale ahead previous state
estim year like instrument increas full year
guidanc jakafi revenu rang vs prior
guidanc base result quarter
also increas estim year model
revenu slightli midpoint current guidanc rang
revenu stream includ jakavi olumi royalti
mostli line estim report iclusig net
product revenu eu estim
jakavi oluminat royalti receiv
novarti nv nr nr line estim
also realiz revenu relat up-front fee
collabor zai lab zlab op
net debt total capit
price-to-earnings lt ep growth
net debt total capit calcul use bv
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep
pleas refer page import disclosur price chart analyst certif
gravita remain key upcom binari event view
import pend catalyst top-line data
trial phase program agent itacitinib
steroid nave acut graft vs host diseas gvhd could move
jak frontlin believ expect high program
posit given clinic result jakafi similar steroid refractori
set well better expect commerci uptak
jakafi line set note rel littl
data releas agent date assess full profil drug
recal phase data patient present
lead decis go forward dose given rate
thrombocytopenia observ given high expect
success remain cautiou ahead binari catalyst appear
garner littl scrutini investor date
beyond gravita pipelin develop program updat
larg anticip also gvhd recent report
posit top-line result phase trial jakafi
steroid-refractori acut gvhd also disclos result
phase trial steroid-refractori chronic gvhd
expect vs prior comment call seem
measur regard opportun could expand jakafi
chronic set compet imbruvica trial
continu unmodifi follow disclos interim analysi efficaci
safeti also provid increment updat pipelin
program includ submiss nda pemigatinib fgfr
inhibitor base posit data trial biomark
select r/r cholangiocarcinoma esmo submiss
repres tangibl movement pipelin view
albeit one expect also announc initi
tumor agnost trial expand pemigatinib patient
fgfr mutat transloc solid tumor broadli
rate corp share market perform pt commerci stage
biotechnolog compani develop drug modul pathway involv cell signal
oncolog autoimmun disord compani solid backbon revenu lead
asset jakafi oral inhibitor jak pathway estim worth per share
howev see compani execut goal diversifi revenu see stock
fulli valu favor upcom catalyst potenti competit fedratinib gener
eros anticip promis asset pipelin topic
jakafi gvhd think opportun alreadi reflect share howev
share could repres good invest investor longer term horizon beyond
one year valuat will invest mid-cap biotechnolog compani solid financi
fundament driven grow commerci backbon anticip minim volatil
clinical/regulatori event
use risk-adjust sum-of-the-part methodolog valu examin clinic
regulatori commerci risk opportun individu indic region
assign probabl success account likelihood achiev
revenues/expens risk-adjust sum-of-the-part analysi appli discount rate
cash flow gener asset determin total net present valu
risk-adjust asset total npv reflect remain clinic regulatori risk
productpeak revenu mn phase developmentnpv mn probabl successrisk-adjust npv mn expect launchnet current value/sharejakafi polycythemia eu us ra eu ra ad indic inhibit fgfr fl mcl cmet ww jak atop jak oncolog pipelinei ii asset share count total risk-adjust equiti valu risk residu non-deplet profitabilityincyt corpor mf/pvolumianticlusigjak jakearli oncolog pipelin corpor
commerci risk competit compani develop treatment myelofibrosi
polycythemia vera therapeut area compet repres risk
clinic risk clinic trial failur incyt compound develop includ itacitinib
pemigatinib ruxolitinib compani earli stage pipelin repres risk
current valuat
regulatori risk even posit clinic data regulatori approv need market
prescript drug develop market regul may declin approv applic
incyt development-stag compound repres risk current valuat
companyprogram/drugtherapeut areaeventtimingev typetri phaseincyteitacitinibgraft vs host diseasedata phiii trial acut trial dataphiiiincytepemigatinibbladd cancerdata phii trial pemigatinib metastat bladder cancer trial lymphomapotenti data phii r/r trial zone lymphomapotenti data phii r/r trial cell lymphomapotenti data phii r/r trial datapiiincytetop ruxolitinibatop dermatitisdata phiii true-ad trial topic ruxolitinib mild-moder trial dataphiiiincytejakafigraft vs host diseasedata phiii trial steroid refractori chronic trial lymphomapotenti nda submiss r/r fl base data phii zone lymphomapotenti nda submiss r/r mzl base data phii cell lymphomapotenti nda submiss r/r mcl base data phii cancerpotenti nda submiss bladder cancer base vs host diseasepotenti nda file acut gvhd base vs host diseasepotenti snda file steroid refractori gvhd base cancerdata phii trial high r/r endometri trial cell carcinomadata phii tiral merkel cell trial cancerdata phii trial r/r anal trial cancerpotenti bla file endometri cell carcinomapotenti bla file merkel cell cancerpotenti bla file anal vs host diseasedata trial chronic initiationphiiiincyt catalyst corpor
 mn except ep
product revenu
chang fair valu acquisition-rel conting consider
interest incom net
loss repurchas senior note
expens relat convers
unreal gains-to-loss long-term invest
earn tax ebt
balanc sheet mn
compani report svb leerink estim
